Terns Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US8808811074
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

SecurityTERN / Terns Pharmaceuticals, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership3,465,307 shares
Ownership 4.10%
Citadel Advisors Llc ownership in TERN / Terns Pharmaceuticals, Inc.

2025-02-14 - Citadel Advisors Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,465,307 shares of Terns Pharmaceuticals, Inc. (US:TERN). This represents 4.1 percent ownership of the company.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (TERN) in the form of stock options. The firm currently holds call options representing 199,800 of underlying shares valued at $10,533,456 USD and put options representing 328,700 of underlying shares valued at $17,329,064 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2025-02-14 2025-02-14 13G/A 3,465,307 4.10 -22.64
2024-07-22 2024-07-22 13G 5.30

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TERN / Terns Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TERNS PHARMACEUTICALS COM 880881107 3,218,810 52,168 1.65 169,696 32.64 0.0242
2026-02-17 2025-12-31 13F TERNS PHARMACEUTICALS COM 880881107 3,166,642 1,577,308 99.24 127,932 971.91 0.0192
2025-11-14 2025-09-30 13F TERNS PHARMACEUTICALS COM 880881107 1,589,334 -2,309,677 -59.24 11,936 -17.93 0.0018
2025-08-14 2025-06-30 13F TERNS PHARMACEUTICALS COM 880881107 3,899,011 -8,876 -0.23 14,543 34.84 0.0025
2025-05-15 2025-03-31 13F TERNS PHARMACEUTICALS COM 880881107 3,907,887 640,108 19.59 10,786 -40.42 0.0020
2025-02-14 2024-12-31 13F TERNS PHARMACEUTICALS COM 880881107 3,267,779 -405,447 -11.04 18,103 -40.91 0.0031
2024-11-14 2024-09-30 13F TERNS PHARMACEUTICALS COM 880881107 3,673,226 2,213,276 151.60 30,635 208.13 0.0059
2024-08-14 2024-06-30 13F TERNS PHARMACEUTICALS COM 880881107 1,459,950 -1,505,636 -50.77 9,942 -48.89 0.0020
2024-05-15 2024-03-31 13F TERNS PHARMACEUTICALS COM 880881107 2,965,586 2,930,946 8,461.16 19,454 8,584.82 0.0038
2024-02-14 2023-12-31 13F TERNS PHARMACEUTICALS COM 880881107 34,640 -41,102 -54.27 225 -41.05 0.0000
2023-11-14 2023-09-30 13F TERNS PHARMACEUTICALS COM 880881107 75,742 74,286 5,102.06 381 3,066.67 0.0001
2023-08-14 2023-06-30 13F TERNS PHARMACEUTICALS COM 880881107 1,456 -390,609 -99.63 13 -99.74 0.0000
2023-05-15 2023-03-31 13F TERNS PHARMACEUTICALS COM 880881107 392,065 -123,732 -23.99 4,642 -11.58 0.0010
2023-02-14 2022-12-31 13F TERNS PHARMACEUTICALS COM 880881107 515,797 515,797 5,251 0.0012
2022-11-14 2022-09-30 13F TERNS PHARMACEUTICALS COM 880881107 0 -38,810 -100.00 0 -100.00
2022-08-15 2022-06-30 13F TERNS PHARMACEUTICALS COM 880881107 38,810 38,810 96 0.0000
2022-03-11 2021-09-30 13F/A-1 TERNS PHARMACEUTICALS COM 880881107 0 -18,200 -100.00 0 -100.00
2021-11-15 2021-09-30 13F TERNS PHARMACEUTICALS COM 880881107 0 -18,200 0
2021-08-16 2021-06-30 13F TERNS PHARMACEUTICALS COM 880881107 18,200 -14,421 -44.21 223 -68.94 0.0000
2021-05-21 2021-03-31 13F/A-1 TERNS PHARMACEUTICALS COM 880881107 32,621 32,621 718 0.0002
2021-05-17 2021-03-31 13F TERNS PHARMACEUTICALS COM 880881107 32,621 32,621 718 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F TERNS PHARMACEUTICALS COM Call 199,800 42.41 10,533 85.83 n/a n/a n/a
2026-02-17 2025-12-31 13F TERNS PHARMACEUTICALS COM Call 140,300 151.43 5,668 1,252.74 n/a n/a n/a
2025-11-14 2025-09-30 13F TERNS PHARMACEUTICALS COM Call 55,800 419 n/a n/a n/a
2025-08-14 2025-06-30 13F TERNS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F TERNS PHARMACEUTICALS COM Call 118,700 -39.90 328 -70.11 n/a n/a n/a
2025-02-14 2024-12-31 13F TERNS PHARMACEUTICALS COM Call 197,500 52.63 1,094 1.39 n/a n/a n/a
2024-11-14 2024-09-30 13F TERNS PHARMACEUTICALS COM Call 129,400 102.50 1,079 148.05 n/a n/a n/a
2024-08-14 2024-06-30 13F TERNS PHARMACEUTICALS COM Call 63,900 763.51 435 806.25 n/a n/a n/a
2024-05-15 2024-03-31 13F TERNS PHARMACEUTICALS COM Call 7,400 -52.87 49 -52.48 n/a n/a n/a
2024-02-14 2023-12-31 13F TERNS PHARMACEUTICALS COM Call 15,700 -19.07 102 4.12 n/a n/a n/a
2023-11-14 2023-09-30 13F TERNS PHARMACEUTICALS COM Call 19,400 1.04 98 -42.26 n/a n/a n/a
2023-08-14 2023-06-30 13F TERNS PHARMACEUTICALS COM Call 19,200 168 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F TERNS PHARMACEUTICALS COM Put 328,700 250.80 17,329 357.83 n/a n/a n/a
2026-02-17 2025-12-31 13F TERNS PHARMACEUTICALS COM Put 93,700 559.86 3,785 3,470.75 n/a n/a n/a
2025-11-14 2025-09-30 13F TERNS PHARMACEUTICALS COM Put 14,200 -84.13 107 -68.17 n/a n/a n/a
2025-08-14 2025-06-30 13F TERNS PHARMACEUTICALS COM Put 89,500 -32.50 334 -8.77 n/a n/a n/a
2025-05-15 2025-03-31 13F TERNS PHARMACEUTICALS COM Put 132,600 75.40 366 -12.68 n/a n/a n/a
2025-02-14 2024-12-31 13F TERNS PHARMACEUTICALS COM Put 75,600 -67.23 419 -78.27 n/a n/a n/a
2024-11-14 2024-09-30 13F TERNS PHARMACEUTICALS COM Put 230,700 808.27 1,924 1,018.60 n/a n/a n/a
2024-08-14 2024-06-30 13F TERNS PHARMACEUTICALS COM Put 25,400 32.29 173 37.60 n/a n/a n/a
2024-05-15 2024-03-31 13F TERNS PHARMACEUTICALS COM Put 19,200 34.27 126 35.87 n/a n/a n/a
2024-02-14 2023-12-31 13F TERNS PHARMACEUTICALS COM Put 14,300 2.88 93 33.33 n/a n/a n/a
2023-11-14 2023-09-30 13F TERNS PHARMACEUTICALS COM Put 13,900 -46.54 70 -69.60 n/a n/a n/a
2023-08-14 2023-06-30 13F TERNS PHARMACEUTICALS COM Put 26,000 228 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.